Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas

Yago Nieto, MD PhD, Peter F Thall, Benigno C Valdez, PhD, Junsheng Ma, MS, Melissa Timmons, Michelle Trapp, Sairah Ahmed, MD, Elizabeth J Shpall, MD, Roy B Jones, MDPhD, Chitra Hosing, MD, Paolo Anderlini, Uday Popat, MD, Muzaffar H. Qazilbash, MD, Amin Alousi, MD, Alison M Gulbis, PharmD, Celina Ledesma, Richard E. Champlin, MD, Borje S Andersson, MDPhD

Blood (2017) 130 (Supplement 1): 1966.

https://doi.org/10.1182/blood.V130.Suppl_1.1966.1966

Published: 2017

Journal Articles

Lenalidomide with Ipilimumab for Lymphoid Malignancies after Allogeneic or Autologous Stem Cell Transplantation (SCT)

Issa F. Khouri, MD, Irina Fernandez Curbelo, PhD, Francesco Turturro, MD, Denái R. Milton, Rang A Kim, Elias J. Jabbour, MD, Roland L Bassett, Jr., Luis M Vence, PhD, Padmanee Sharma, MD PhD, Alison M Gulbis, PharmD

Blood (2016) 128 (22): 1164.

https://doi.org/10.1182/blood.V128.22.1164.1164

Published: 2016

Journal Articles

Ofatumumab Plus Ifosfamide/Etoposide (OIE) Followed By Autologous Stem Cell Transplantation (ASCT) in Patients with b-Cell Non-Hodgkin's Lymphomas (NHL)

Issa F. Khouri, MD, Francesco Turturro, MD, Denái R. Milton, Martin Korbling, MD, Barry I Samuels, BA, MD, Elias J. Jabbour, MD, Celina Ledesma, BS, Rosamar B Valverde, Hui Gao, PhD, Michelle A Fanale, MD, Luis E. Fayad, MD, Loretta J. Nastoupil, MD, James M Reuben, BS, MBA, MS, PhD, Alison M Gulbis, PharmD

Blood (2016) 128 (22): 5814.

https://doi.org/10.1182/blood.V128.22.5814.5814

Published: 2016

Journal Articles

Stratified Intense-Dose- Yttrium-90 Ibritumumab Tiuxetan ( 90 YIT ) with Bendamustine+Fludarabine Nonmyeloablative Conditioning for Allogeneic Stem Cell Transplantation in b-Cell Malignancies

Issa F. Khouri, MD, Bill Erwin, MS, Alison M Gulbis, PharmD, Francesco Turturro, MD, S Cheenu Kappadath, PhD, Dustin Gress, MS, Rosamar B Valverde, Elias J. Jabbour, MD, Roland L Bassett, Jr., Aaron Jessop, MBA,MD

Blood (2016) 128 (22): 662.

https://doi.org/10.1182/blood.V128.22.662.662

Published: 2016

Journal Articles

Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL)

Issa F. Khouri, MD, Rima M Saliba, PhD, Zijun Y. Xu-Monette, PhD, Martin Korbling, MD, Gabriela Rondon, MD, Rosamar Valverde, Amin M. Alousi, MD, Paolo Anderlini, MD, Sairah Ahmed, MD, Stefan O Ciurea, MD, Luis Fayad, MD, Betul Oran, MD, Simrit Parmar, Uday R. Popat, MD, Jason R. Westin, MD, Francesco Turturro, MD, L. Jeffrey Medeiros, MD, Alison M Gulbis, PharmD, BCOP, Ken H. Young, MD PhD

Blood (2014) 124 (21): 2563.

https://doi.org/10.1182/blood.V124.21.2563.2563

Published: 2014

Journal Articles

A Lower Dose Of Melphalan (140 mg/m 2 ) As Preparative Regimen For Multiple Myeloma In Patients >65 Or With Renal Dysfunction

Ila Maewal Saunders, PharmD, Alison M Gulbis, PharmD, BCOP, Richard E Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2013) 122 (21): 5536.

https://doi.org/10.1182/blood.V122.21.5536.5536

Published: 2013

Journal Articles

Ofatumumab Plus Chemotherapy Followed By G-CSF For Mobilization Of Peripheral Blood Stem Cells (PBSC) In Patients With B-Cell Non-Hodgkin’s Lymphomas (NHL)

Issa F. Khouri, MD, Hui Gao, PhD, Wei Wei, MS, Martin Korbling, MD, Celina Ledesma, BS, Rosamar Valverde, MD, Alison M Gulbis, PharmD, BCOP, James M Reuben, PhD

Blood (2013) 122 (21): 4518.

https://doi.org/10.1182/blood.V122.21.4518.4518

Published: 2013

Journal Articles

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis

Issa F. Khouri, MD, Rima M. Saliba, Ph.D., Pramoda Challagundla, Celina Ledesma, Martin Korbling, MD, Alison M Gulbis, PharmD, BCOP, Maria Guillermo-Pacheco, Sairah Ahmed, MD, Paolo Anderlini, MD, Qaiser Bashir, MD, Betul Oran, MD, Stefan O Ciurea, MD, Chitra M. Hosing, MD, Partow Kebriaei, MD, Uday R Popat, MD, Elias Jabbour, MD, Richard E Champlin, MD, Jeffrey L. Jorgensen, MD, PhD

Blood (2013) 122 (21): 3349.

https://doi.org/10.1182/blood.V122.21.3349.3349

Published: 2013

Journal Articles

Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan ( 90 YIT)

Issa F. Khouri, MD, Rima M. Saliba, Ph.D., Zijun Y Xu-Monette, MD, Gabriela Rondon, MD, Rosamar Valverde, MD, Martin Korbling, MD, Alison M Gulbis, PharmD, BCOP, Paolo Anderlini, MD, Ahmed Sairah, MD, Chitra M. Hosing, MD, Uday R Popat, MD, Partow Kebriaei, MD, Luis E Fayad, Jason R. Westin, MD, Francesco Turturro, MD, L. Jeffrey Medeiros, MD, Richard E Champlin, MD, Ken H. Young, MD, PhD

Blood (2013) 122 (21): 3350.

https://doi.org/10.1182/blood.V122.21.3350.3350

Published: 2013

Journal Articles

Modified-CVAD Or Modified-Cbad Compared To High Dose Cyclophosphamide For Peripheral Blood Stem Cell Mobilization In Patients With Multiple Myeloma

Suzanne C Gettys, PharmD, Alison M Gulbis, PharmD, BCOP, Kaci Wilhelm, PharmD, BCOP, Yvonne T Dinh, Gabriela Rondon, MD, Muzaffar H. Qazilbash, MD

Blood (2013) 122 (21): 2036.

https://doi.org/10.1182/blood.V122.21.2036.2036

Published: 2013

Journal Articles

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression

Issa F. Khouri, MD, Wei Wei, MS, Rosamar Valverde, MD, Martin Korbling, MD, Francesco Turturro, MD, Alison M Gulbis, PharmD, BCOP, Maria Guillermo-Pacheco, Sairah Ahmed, MD, Amin Alousi, MD, Betul Oran, MD, Paolo Anderlini, MD, Stefan O Ciurea, MD, Chitra M. Hosing, MD, Uday R Popat, MD, Elias Jabbour, MD, Richard E Champlin, MD, Roland Bassett

Blood (2013) 122 (21): 541.

https://doi.org/10.1182/blood.V122.21.541.541

Published: 2013

Journal Articles

Linezolid Use in Hematopoietic Stem Cell Transplantation: A Cautionary Tale

Alison M Gulbis, PharmD, Musa Yilmaz, MD, Dawen Sui, MS, Roland L Bassett, Jr., MS, Zandra R Rivera, RN, MS, ANP-BC, Richard E. Champlin, Marcos De Lima, MD

Blood (2012) 120 (21): 4534.

https://doi.org/10.1182/blood.V120.21.4534.4534

Published: 2012

NARROW

Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas

Lenalidomide with Ipilimumab for Lymphoid Malignancies after Allogeneic or Autologous Stem Cell Transplantation (SCT)

Ofatumumab Plus Ifosfamide/Etoposide (OIE) Followed By Autologous Stem Cell Transplantation (ASCT) in Patients with b-Cell Non-Hodgkin's Lymphomas (NHL)

Stratified Intense-Dose- Yttrium-90 Ibritumumab Tiuxetan ( 90 YIT ) with Bendamustine+Fludarabine Nonmyeloablative Conditioning for Allogeneic Stem Cell Transplantation in b-Cell Malignancies

Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL)

A Lower Dose Of Melphalan (140 mg/m 2 ) As Preparative Regimen For Multiple Myeloma In Patients >65 Or With Renal Dysfunction

Ofatumumab Plus Chemotherapy Followed By G-CSF For Mobilization Of Peripheral Blood Stem Cells (PBSC) In Patients With B-Cell Non-Hodgkin’s Lymphomas (NHL)

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis

Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan ( 90 YIT)

Modified-CVAD Or Modified-Cbad Compared To High Dose Cyclophosphamide For Peripheral Blood Stem Cell Mobilization In Patients With Multiple Myeloma

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression

Linezolid Use in Hematopoietic Stem Cell Transplantation: A Cautionary Tale

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only